173 related articles for article (PubMed ID: 33432347)
1. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.
Wang S; Wei H; Huang Z; Wang X; Shen R; Wu Z; Lin J
Acta Biochim Biophys Sin (Shanghai); 2021 Mar; 53(3):317-324. PubMed ID: 33432347
[TBL] [Abstract][Full Text] [Related]
2. lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
Sun ZY; Jian YK; Zhu HY; Li B
Pathol Res Pract; 2019 Mar; 215(3):555-563. PubMed ID: 30661902
[TBL] [Abstract][Full Text] [Related]
3. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
[TBL] [Abstract][Full Text] [Related]
4. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.
Yang M; Zhang T; Zhang Y; Ma X; Han J; Zeng K; Jiang Y; Wang Z; Wang Z; Xu J; Hua Y; Cai Z; Sun W
J Exp Clin Cancer Res; 2021 May; 40(1):166. PubMed ID: 33980265
[TBL] [Abstract][Full Text] [Related]
5. EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
Sevelda F; Mayr L; Kubista B; Lötsch D; van Schoonhoven S; Windhager R; Pirker C; Micksche M; Berger W
J Exp Clin Cancer Res; 2015 Nov; 34():134. PubMed ID: 26526352
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA KCNQ1OT1 contributes to tumor growth and activates Wnt/β‑catenin signaling in osteosarcoma by targeting the miR‑3666/KLF7 axis.
Huang A; Jin S; Han W; Wang Y; Ma S; Wang Z; Lin K; Zou Q; Zhou J; Li Z; Chen L
Int J Mol Med; 2021 Jan; 47(1):387-396. PubMed ID: 33416089
[TBL] [Abstract][Full Text] [Related]
7. Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Huang CY; Wei PL; Wang JW; Makondi PT; Huang MT; Chen HA; Chang YJ
Dis Markers; 2019; 2019():4569718. PubMed ID: 30719181
[TBL] [Abstract][Full Text] [Related]
8. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
9. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract][Full Text] [Related]
10. Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways.
Wang Y; Wang S; Liu J; Lu Y; Li D
Chem Biol Interact; 2018 Jun; 290():44-51. PubMed ID: 29782821
[TBL] [Abstract][Full Text] [Related]
11. MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion.
Wang Q; Cai J; Wang J; Xiong C; Zhao J
Tumour Biol; 2014 Dec; 35(12):12743-8. PubMed ID: 25227664
[TBL] [Abstract][Full Text] [Related]
12. Autophagy in osteosarcoma.
O'Farrill JS; Gordon N
Adv Exp Med Biol; 2014; 804():147-60. PubMed ID: 24924173
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
[TBL] [Abstract][Full Text] [Related]
14. CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.
Tsai HC; Huang CY; Su HL; Tang CH
PLoS One; 2014; 9(3):e90159. PubMed ID: 24637722
[TBL] [Abstract][Full Text] [Related]
15. LncRNA FER1L4 induces apoptosis and suppresses EMT and the activation of PI3K/AKT pathway in osteosarcoma cells via inhibiting miR-18a-5p to promote SOCS5.
Ye F; Tian L; Zhou Q; Feng D
Gene; 2019 Dec; 721():144093. PubMed ID: 31473323
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
17. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA
Li H; Lan M; Liao X; Tang Z; Yang C
Technol Cancer Res Treat; 2020; 19():1533033819898728. PubMed ID: 31960764
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
20. LINC00514 drives osteosarcoma progression through sponging microRNA-708 and consequently increases URGCP expression.
Yu D; Xu X; Li S; Zhang K
Aging (Albany NY); 2020 Apr; 12(8):6793-6807. PubMed ID: 32325430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
